News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Two More China Biopharmas, Xiangxue Pharmaceutical and Guangdong By-Health Biotechnology to IPO on ChiNext Exchange
November 29, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
November 26, 2010 -- Two China biopharmas, Xiangxue Pharmaceutical and Guangdong By-Health Biotechnology, have released prospectuses for their IPOs on the ChiNext exchange. More details....
Twitter
LinkedIn
Facebook
Email
Print
Asia
MORE ON THIS TOPIC
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
·
1 min read
·
Tristan Manalac
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
·
2 min read
·
Nick Paul Taylor
China
China plans to transform biotech sector into $522B powerhouse by 2030
September 18, 2026
·
2 min read
·
Annalee Armstrong
